Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Eli Lilly (LLY) will report Q1 results on Thursday. Analysts expect in line results with focus on tirizepatide and obesity franchise.

shares traded higher in the premarket on Tuesday as Goldman Sachs upgraded the weight loss drugmaker, citing an attractive entry point. Analyst Asad Haider, who assumed LLY’s coverage from BofA ...

Eli Lilly (LLY) has ended a three-day selloff after Goldman Sachs analyst Asad Haider upgraded the Indiana-based drugmaker to Buy from Neutral, citing an attractive entry point given its ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

On Tuesday, Goldman Sachs analyst Asad Haider upgraded shares of healthcare giant Johnson & Johnson (NYSE:JNJ) from "Neutral" to "Buy," simultaneously raising the price target to $172 from the ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share ...

Goldman Sachs analyst Asad Haider resumed coverage with a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of $172.00. The company’s shares opened today ...

On Tuesday, Goldman Sachs (NYSE:GS) analyst Asad Haider upgraded shares of healthcare giant Johnson & Johnson (NYSE:JNJ) from "Neutral" to "Buy," simultaneously raising the price target to $172 from ...

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is ...